Stock Taper
EVGN
EVOGENE LTD.
NASDAQ
$0.56
▲ UP 0.36% (0.00)

KEY STATISTICS

Market Cap$4.85 M
52w High$1.50
52w Low$0.37
Dividend Yield
Frequency
P/E-0.22
Volume1.04M
Shares Out.8.62M

COMPANY

LEADERSHIP

Ofer Haviv
CHIEF EXECUTIVE
Ofer Haviv

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 15, 2010
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
52

PRICE TARGET

Target High$2.15
Target Low$2.15
Target Median$2.15
Target Consensus$2.15

UPCOMING EARNINGS

DateNov 18, 2026
DayWednesday
Rev. Est.$400.00K
NOV
18
WED

SPLIT RECORD

DATETYPERATIO
2024-07-25Reverse1:10
2013-11-19Reverse1:2

PRICE

$0.56 ▲ UP 0.36% (+$0.00)
OVERLAYS
$0.55$0.579:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM0.56

About Evogene Ltd.

https://www.evogene.com ↗

Evogene Ltd. leverages AI and big data through its CPB platform to develop innovative products across agriculture, human health, and industrial sectors worldwide.

INDUSTRY

Biotechnology

A SERVICE EVOGENE LTD. IS KNOWN FOR

ChemPass AI

Evogene's proprietary generative AI platform accelerates the discovery and optimization of novel small molecules for pharma and agriculture, enhancing potency, success rates, and reducing development time and costs for partners.

INSTITUTIONAL OWNERSHIP

SHARES OWNED
4.40%
HOLDERS
3
TOP 3 OF 3 · RANKED BY POSITION SIZE
Delek Group, Ltd.
211.1K sh · $332K
Eidelman Virant Capital
117.0K sh · $96K
Ubs AG
50.9K sh · $669K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

DIRECTOR
RECANATI LEON
Purchase · 460.0K shares
2026-08-11
DIRECTOR
RECANATI LEON
Purchase · 800.0K shares
2026-08-04
OFFICER: VP FINANCE
Ravzin Polina
· 3.0K shares
2026-02-03
OFFICER: VP FINANCE
Ravzin Polina
· 1.5K shares
2026-04-01

SECTORS PEERS

PEERPRICE
DWTX$2.49COMPARE
CING$5.55COMPARE
MRKR$1.39COMPARE
CLRB$2.59COMPARE
COCP$1.15COMPARE
AEON$0.19COMPARE
BOLT$3.67COMPARE
IMNN$1.64COMPARE